The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Epcoritamab in combination with R-CHOP or lenalidomide for Richter’s transformation
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, discusses outcomes of epcoritamab combined with R-CHOP or lenalidomide for the treatment of Richter’s transformation. Prof. Kater highlights that epcoritamab montherapy demonstrates efficacy, but also has potential in combination with classical therapies such as chemotherapy or immunomodulators. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Immediately after that we have another abstract by Phil Thompson from Australia, and he uses kind of a follow-up study, of course much shorter follow-up because it’s a follow-up study, where epcoritamab in the same patient group was combined with either R-CHOP, so the standard treatment for chemoimmunotherapy, or with lenalidomide. And for the R-CHOP treatment, those patients should have been treatment-naïve...
Immediately after that we have another abstract by Phil Thompson from Australia, and he uses kind of a follow-up study, of course much shorter follow-up because it’s a follow-up study, where epcoritamab in the same patient group was combined with either R-CHOP, so the standard treatment for chemoimmunotherapy, or with lenalidomide. And for the R-CHOP treatment, those patients should have been treatment-naïve. And there it was seen that, although what I already told is that epcoritamab by itself has a merit and has efficacy in this very poor prognosis disease, but if you combine it with either R-CHOP at first line or lenalidomide in later lines, that also directly you get a better outcome. And it seems to be better if you combine it with monotherapy, showing that epcoritamab is a very good drug to partner with classical treatments like chemotherapy, but also with an immunomodulator like lenalidomide.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
